Asunto(s)
Personajes , Vuelo Espacial/historia , Historia del Siglo XX , Humanos , Federación de RusiaRESUMEN
The study of the effects of hemodialysis on the course and outcomes of severe acetic acid (AA) poisoning has shown that use of hemodialysis leads to a significant reduction of lethality (from 78.2 to 46.9%), lethality in acute renal failure (by 20%), of the number of patients who died of exotoxic shock within 24 hours after the poisoning (from 71 to 60%).
Asunto(s)
Ácido Acético/efectos adversos , Intoxicación/terapia , Diálisis Renal/métodos , Adulto , Anciano , Femenino , Lavado Gástrico , Humanos , Masculino , Persona de Mediana EdadRESUMEN
12 patients with rapidly progressive systemic lupus erythematosus (SLE) combined with renal failure were treated for 6 months according to the following scheme: 3 consecutive procedures of plasmapheresis (60 ml/kg x 3), 3 consecutive pulse doses of cyclophosphamide (400 mg/m2 x 3), 3 prednisolone infusions (2 mg/kg x 3), oral cyclophosphamide (100-250 mg/day) and prednisolone (0.5 mg/kg with subsequent dose reduction). Dose of the drugs was controlled by blood leukocyte count and creatinine clearance. The patients were included in the trial in the preset time. All the patients had active SLE (33.5 +/- 2.7 U according to SLAM). 75, 25, 58.3, 33.4, 8.3% of patients had mixed, nephrotic, mesangiocapillary, mesangioproliferative, membraneous nephritis, respectively. 26 weeks of the treatment produced a response in 83.3% of the patients. The disease activity lowered to 12.8 +/- 2.9 U. Four-year survival reached 81%. Cytopenia developed in 25% of patients, deep hemopoiesis depression was not observed. Septic candidiasis arose in one woman on the third year of the follow-up. Clinical validity of the above method is stated in severe SLE.
Asunto(s)
Ciclofosfamida/administración & dosificación , Inmunosupresores/uso terapéutico , Lupus Eritematoso Sistémico/terapia , Nefritis Lúpica/terapia , Plasmaféresis , Adulto , Terapia Combinada , Ciclofosfamida/efectos adversos , Progresión de la Enfermedad , Quimioterapia Combinada , Femenino , Humanos , Inmunosupresores/efectos adversos , Lupus Eritematoso Sistémico/complicaciones , Nefritis Lúpica/complicaciones , Masculino , Prednisolona/administración & dosificación , Inducción de Remisión , Factores de TiempoAsunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Cirugía Bucal , Tolmetina/análogos & derivados , Trometamina/análogos & derivados , Antiinflamatorios no Esteroideos/efectos adversos , Evaluación de Medicamentos , Femenino , Humanos , Ketorolaco Trometamina , Masculino , Dolor Postoperatorio/tratamiento farmacológico , Tolmetina/efectos adversos , Tolmetina/uso terapéutico , Trometamina/efectos adversos , Trometamina/uso terapéuticoAsunto(s)
Analgésicos no Narcóticos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Periodontitis/tratamiento farmacológico , Pulpitis/tratamiento farmacológico , Tolmetina/análogos & derivados , Trometamina/uso terapéutico , Adulto , Anciano , Terapia Combinada , Combinación de Medicamentos , Evaluación de Medicamentos , Femenino , Humanos , Ketorolaco Trometamina , Masculino , Persona de Mediana Edad , Tratamiento del Conducto Radicular , Tolmetina/uso terapéuticoRESUMEN
Based on the authors' experience from 1982 to 1990 it was noted that out of 26 cases of renal amyloidosis in the presence of nonpurulent and purulent conditions 2 patients (7%) demonstrated the association with systemic lupus erythematosus (SLE). It was also noted that amyloidosis developed in the patients with a long history of the disease. Long-course immunosuppression treatment could be regarded as the other factor-of-risk for amyloidosis development. Histochemical examination of both patients demonstrated that amyloid deposits in the renal glomeruli were resistant to the potassium permanganate effect and consisted of AL-protein. The results obtained indicated the possibility of appearance of immunoglobulins AL--the proteins of the primary amyloidosis--synthesized in the spectrum in the SLE presence as well as their deposition in the renal glomeruli. As a possible cause of proteinuria and the nephrotic syndrome in SLE patients amyloidosis should be diagnosed in the life time and be regarded in the choice of therapeutic policy as well as in the assessment of pulse immunosuppressive therapy practicability.
Asunto(s)
Amiloidosis/complicaciones , Enfermedades Renales/complicaciones , Lupus Eritematoso Sistémico/complicaciones , Adolescente , Adulto , Amiloidosis/etiología , Amiloidosis/patología , Biopsia , Femenino , Humanos , Riñón/patología , Enfermedades Renales/patología , Lupus Eritematoso Sistémico/patología , Masculino , Factores de RiesgoRESUMEN
The modification of "quadelmethod" of determining local anesthetic effects of drugs is described. A magnetoelectric sensor which is interference-proof, reliable at work and does not need additional power supply and an amplifier was used for registration of the animal respiration.
Asunto(s)
Anestesia de Conducción/métodos , Anestésicos Locales , Dimensión del Dolor/métodos , Animales , Magnetismo , ConejosRESUMEN
The derivatives of a novel structure series of dibenzazepines dispose of intense antiarrhythmic properties. The relations between structure and effect in comparison with the antiarrhythmically active derivatives of phenothiazine (Ethmozine) are discussed. When substituting the beta-aminopropionyl chain with cyclic residue by means of a dimethylaminoacyl chain there appears a marked antifibrillatory action besides of the intense antiarrhythmic one. The compound 17, the 3-carbethoxyamino-5-dimethylaminoacetyl-dibenzazepine, proved to be the most efficacious compound in the course of the basic screening on two models: action on the effective refractory period in the rabbit's atrium and aconitin-induced arrhythmia in the conscious rat. In comparison with Ethmozin, an antiarrhythmic agent of the phenothiazine type, 17 shows a somewhat lower efficacy in case of i.v. application, but a distinctly intenser one was stated after oral administration. A profound test on the models: two-step coronary ligature in the dog according to Harris and electrofibrillation in the cat's heart, revealed an equally intense antiarrhythmic action but a considerably intenser antifibrillatory one. Therefore the compound 17 (abbreviated designation in the USSR: GS 015 or in the GDR: AWD 19-166) was provided for a thorough pharmacological and toxcological study.
Asunto(s)
Antiarrítmicos/síntesis química , Dibenzazepinas/síntesis química , Animales , Antiarrítmicos/farmacología , Antiarrítmicos/toxicidad , Fenómenos Químicos , Química , Dibenzazepinas/farmacología , Dibenzazepinas/toxicidad , Técnicas In Vitro , Dosificación Letal Mediana , Contracción Miocárdica/efectos de los fármacos , Conejos , RatasRESUMEN
Diarrhea that arises in mice given serotonin intravenously is not suppressed by tipindolol, LSD-25, ciproheptadine in doses in which these drugs block the D and T serotonin-reactive structures, or is not reduced by hexonium, thereby providing no evidence in favour of the reflex nature of the effect. Diarrhea is suppressed by morphine and atropine, thus pointing to the responsibility for its origin of M-serotoninoreactive structures of intestinal parasympathetic ganglia with subsequent involvement of the postganglionic cholinergic link.
Asunto(s)
Diarrea/inducido químicamente , Antagonistas de la Serotonina/uso terapéutico , Serotonina/envenenamiento , Animales , Atropina/uso terapéutico , Ciproheptadina/uso terapéutico , Diarrea/tratamiento farmacológico , Compuestos de Hexametonio , Indoles/uso terapéutico , Dietilamida del Ácido Lisérgico/uso terapéutico , Masculino , Ratones , Morfina/uso terapéuticoRESUMEN
Nonachlazin diminishes aseptic inflammation provoked by subplantar administration of carrageenin to rats. Nonachlazin increases the sensitivity pain threshold of the rat paw affected by carrageenin-induced inflammation, decreases the reaction of mice to intraperitoneal injection of phenylchinoin, and the ability of the rabbit central nervous system for impulse summation. Nonachlazin prevents carrageenin-induced temperature rise in rats.
Asunto(s)
Antiinflamatorios no Esteroideos , Nonaclazina/uso terapéutico , Fenotiazinas/uso terapéutico , Animales , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Edema/tratamiento farmacológico , Fiebre/tratamiento farmacológico , Enfermedades del Pie/tratamiento farmacológico , Ratones , Dolor/fisiopatología , Ratas , Umbral Sensorial/efectos de los fármacosRESUMEN
Droperidol, haloperidol and azabutyron inhibit the reactions of rabbit aortal stria caused by stimulation of D-type serotonine receptors. Droperidol appears most active in this respect. Its antiserotonine properties are characterised by certain selectivity. The capacity of droperidol for protection of D-receptors against irreversible dibenamine blockade suggests its indirect interaction with D-receptors.